Roy A. Beveridge - Nov 16, 2021 Form 4 Insider Report for Epizyme, Inc. (EPZM)

Role
Director
Signature
/s/ John Weidenbruch, attorney-in-fact
Stock symbol
EPZM
Transactions as of
Nov 16, 2021
Transactions value $
$0
Form type
4
Date filed
11/18/2021, 07:22 AM
Next filing
Apr 1, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EPZM Common Stock, par value $0.0001 Award $0 +16.7K $0.00 16.7K Nov 16, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EPZM Stock Option (Right to Buy) Award $0 +83.3K $0.00 83.3K Nov 16, 2021 Common Stock 83.3K $4.27 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of shares of Common Stock issuable under 16,702 restricted stock units ("RSUs") granted pursuant to the Issuer's 2013 Stock Incentive Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in three equal annual installments over three years from the grant date, with the first installment vesting on November 16, 2022, subject to continued service as a director. In the event of a change in control of the Issuer, the RSUs will vest in full.
F2 The number of shares of the Common Stock issuable upon exercise of the Option (as defined below) and underlying the RSUs granted to Dr. Beveridge accounts for adjustment based on the terms of the Issuer's non-employee director compensation program, which provides that the aggregate number of shares of Common Stock issuable upon exercise of the initial option grant and underlying the initial RSU grant to each new director shall in no event exceed a total of 100,000 shares.
F3 This option (the "Option") was granted on November 16, 2021 pursuant to the Issuer's 2013 Stock Incentive Plan with respect to 83,298 shares of Common Stock, with 33% vesting on November 16, 2022 and the remaining shares underlying the Option vesting in 24 substantially equal monthly installments thereafter, subject to continued service as a director. In the event of a change in control of the Issuer, the Option will vest in full.